📊 USAQ Key Takeaways
Is QHSLab, Inc. (USAQ) a Good Investment?
While QHSLab demonstrates strong gross margins (67.3%) and revenue growth (+26.3% YoY), critical financial red flags undermine credibility: interest coverage of 0.6x indicates operating income cannot service debt obligations, and a substantial gap between net income ($457.4K) and operating cash flow ($178.1K) signals significant earnings quality concerns. The microscopic revenue base ($2.7M) compounds volatility and sustainability risks.
Why Buy QHSLab, Inc. Stock? USAQ Key Strengths
- Exceptional gross margin of 67.3% indicates strong product positioning and pricing power in medical instruments
- Solid top-line revenue growth of 26.3% YoY demonstrates market demand
- Conservative capital structure with minimal leverage (Debt/Equity 0.06x) reduces financial distress risk
USAQ Stock Risks: QHSLab, Inc. Investment Risks
- Critical interest coverage ratio of 0.6x means operating income cannot cover interest expenses, indicating refinancing dependency
- Severe earnings quality deterioration: net income growth of 276% not supported by operating cash flow growth, suggesting non-cash gains or accounting anomalies
- Microscopic scale ($2.7M revenue) creates severe operational fragility and revenue concentration risks
Key Metrics to Watch
- Interest Coverage Ratio trending back above 1.0x (currently unsustainable at 0.6x)
- Operating Cash Flow convergence with Net Income (currently 61% gap suggests quality issues)
- Revenue growth sustainability beyond current 26.3% YoY pace
QHSLab, Inc. (USAQ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
QHSLab, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
USAQ Profit Margin, ROE & Profitability Analysis
USAQ vs Healthcare Sector: How QHSLab, Inc. Compares
How QHSLab, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is QHSLab, Inc. Stock Overvalued? USAQ Valuation Analysis 2026
Based on fundamental analysis, QHSLab, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
QHSLab, Inc. Balance Sheet: USAQ Debt, Cash & Liquidity
USAQ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: QHSLab, Inc.'s revenue has grown significantly by 90% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
USAQ Revenue Growth, EPS Growth & YoY Performance
USAQ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $544.3K | -$2.9K | $0.00 |
| Q2 2025 | $473.1K | -$2.9K | $0.00 |
| Q1 2025 | $488.6K | -$18.5K | $0.00 |
| Q3 2024 | $336.4K | -$2.9K | $0.00 |
| Q2 2024 | $404.8K | -$2.9K | $0.00 |
| Q1 2024 | $352.8K | -$18.5K | $0.00 |
| Q3 2023 | $269.3K | -$82.4K | $-0.01 |
| Q2 2023 | $350.8K | -$106.7K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
QHSLab, Inc. Dividends, Buybacks & Capital Allocation
USAQ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for QHSLab, Inc. (CIK: 0000856984)
📋 Recent SEC Filings
❓ Frequently Asked Questions about USAQ
What is the AI rating for USAQ?
QHSLab, Inc. (USAQ) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are USAQ's key strengths?
Claude: Exceptional gross margin of 67.3% indicates strong product positioning and pricing power in medical instruments. Solid top-line revenue growth of 26.3% YoY demonstrates market demand.
What are the risks of investing in USAQ?
Claude: Critical interest coverage ratio of 0.6x means operating income cannot cover interest expenses, indicating refinancing dependency. Severe earnings quality deterioration: net income growth of 276% not supported by operating cash flow growth, suggesting non-cash gains or accounting anomalies.
What is USAQ's revenue and growth?
QHSLab, Inc. reported revenue of $2.7M.
Does USAQ pay dividends?
QHSLab, Inc. does not currently pay dividends.
Where can I find USAQ SEC filings?
Official SEC filings for QHSLab, Inc. (CIK: 0000856984) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is USAQ's EPS?
QHSLab, Inc. has a diluted EPS of $0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is USAQ a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, QHSLab, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is USAQ stock overvalued or undervalued?
Valuation metrics for USAQ: ROE of 28.1% (sector avg: 15%), net margin of 17.0% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy USAQ stock in 2026?
Our dual AI analysis gives QHSLab, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is USAQ's free cash flow?
QHSLab, Inc.'s operating cash flow is $178.1K, with capital expenditures of N/A. FCF margin is 6.6%.
How does USAQ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 17.0% (avg: 12%), ROE 28.1% (avg: 15%), current ratio 1.96 (avg: 2).
Why is USAQ's return on equity (ROE) so high?
QHSLab, Inc. has a return on equity of 28.1%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 17.0% net margin.